Literature DB >> 18683194

Methylation-related silencing of p14ARF gene correlates with telomerase activity and mRNA expression of human telomerase reverse transcriptase in hepatocellular carcinoma.

Changsong Zhang1, Xianling Guo, Li Zhang, Zhenghua Lu, Nannan Ma, Yue Cheng, Feng Shen, Baihe Zhang, Mengchao Wu, Lixin Wei.   

Abstract

BACKGROUND AND OBJECTIVES: The p14(ARF) gene encodes a critical negative regulator of cell cycle progression. And upregulation of telomerase activity has been considered a critical step to tumors. We investigated promoter methylation of p14(ARF) and expression as well as their effect on hTERT expression and telomerase activity in HCC.
METHODS: We studied p14(ARF) methylation and mRNA in 30 hepatocellular carcinomas and corresponding non-tumor liver tissues using methylation-specific PCR. Reverse transcription-PCR was performed for expression of p14(ARF) and hTERT. Telomerase activity was performed by TRAP assay.
RESULTS: p14(ARF) hypermethylation was detected in 16 (53.3%) of HCC and 10 (33.3%) of non-tumor tissues, and 12 of 16 with methylation were tumor tissues around large size (> or =5 cm). p14(ARF) mRNA was observed in 25%, 80.0%, or 50.0% of tumors with hypermethylated, partially methylated or unmethylated p14(ARF) promoter, respectively. Among the 16 tumors with p14(ARF) hypermethylation, all 12 tumors lacking p14(ARF) mRNA were positive for hTERT expression, while only one of 4 tumors expressing p14(ARF) mRNA was positive for hTERT expression.
CONCLUSIONS: p14(ARF) hypermethylation may contribute to silencing of p14(ARF) mRNA expression in HCC. Telomerase activity is association with inactivation of the p14(ARF)-p53 pathway induced by methylation in HCC. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18683194     DOI: 10.1002/jso.21131

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  Aberrant CpG island hypermethylation and down-regulation of Oct-6 mRNA expression in human hepatocellular carcinoma.

Authors:  Jing-Zhe Sun; Xue-Xi Yang; Xiang-Hong Li; Wei-Wen Xu; Ying Wang; Wei Zhu; Ming Li
Journal:  Dig Dis Sci       Date:  2011-03-30       Impact factor: 3.199

Review 2.  P15 gene methylation in hepatocellular carcinomas: a systematic review and meta-analysis.

Authors:  Wei-Hua Ren; Ya-Wei Li; Rui Li; Hong-Bo Feng; Jun-Long Wu; Hui-Rui Wang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Promoter hypermethylation of the RECK gene is associated with its low expression and poor survival of esophageal squamous cell carcinoma.

Authors:  Jing Zhu; Yang Ling; Yun Xu; Mingzhu Lu; Yongping Liu; Changsong Zhang
Journal:  Oncol Lett       Date:  2017-01-27       Impact factor: 2.967

4.  The silencing of RECK gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma.

Authors:  Changsong Zhang; Yang Ling; Chenghui Zhang; Yun Xu; Lu Gao; Rong Li; Jing Zhu; Lieying Fan; Lixin Wei
Journal:  Int J Biol Sci       Date:  2012-03-03       Impact factor: 6.580

5.  Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma.

Authors:  A Aigelsreiter; A L Ress; K Bettermann; S Schauer; K Koller; F Eisner; T Kiesslich; T Stojakovic; H Samonigg; P Kornprat; C Lackner; J Haybaeck; M Pichler
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

6.  The Correlation Relationship between P14ARF Gene DNA Methylation and Primary Liver Cancer.

Authors:  Hui Zhang; Wanpin Nie; Feizhou Huang
Journal:  Med Sci Monit       Date:  2015-10-12

7.  Biological significance of promoter hypermethylation of p14/ARF gene: relationships to p53 mutational status in Tunisian population with colorectal carcinoma.

Authors:  Ines Chaar; Sameh Amara; Olfa Elhadj Elamine; Mariem Khiari; Donia Ounissi; Taher Khalfallah; Abdelmajid Ben Hmida; Sabeh Mzabi; Saadia Bouraoui
Journal:  Tumour Biol       Date:  2013-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.